95 related articles for article (PubMed ID: 11396752)
41. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
42. A phase II study of a daily x4 schedule of vinorelbine plus cisplatin for advanced non-small cell lung cancer.
Han JY; Kim KW; Kim JA; Kang JH; Jin JY; Hong YS; Park SY; Song JS; Park JW; Kim HK; Lee KS; Choi BG
Jpn J Clin Oncol; 2000 Oct; 30(10):435-9. PubMed ID: 11185889
[TBL] [Abstract][Full Text] [Related]
43. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
[TBL] [Abstract][Full Text] [Related]
44. Vinorelbine, ifosfamide, and cisplatin combination as salvage chemotherapy in advanced non-small cell lung cancer.
Song SY; Kim WS; Kim K; Jung CW; Im YH; Kim HJ; Kang WK; Lee HG; Kwon OJ; Rhee CH; Park CH; Park K
Jpn J Clin Oncol; 2003 Oct; 33(10):509-13. PubMed ID: 14623918
[TBL] [Abstract][Full Text] [Related]
45. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study.
Frasci G; Comella P; Scoppa G; Guida C; Gravina A; Fiore F; Casaretti R; Daponte A; Parziale A; Comella G
J Clin Oncol; 1997 Apr; 15(4):1409-17. PubMed ID: 9193333
[TBL] [Abstract][Full Text] [Related]
46. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.
Khuri FR; Rigas JR; Figlin RA; Gralla RJ; Shin DM; Munden R; Fox N; Huyghe MR; Kean Y; Reich SD; Hong WK
J Clin Oncol; 2001 May; 19(10):2626-37. PubMed ID: 11352954
[TBL] [Abstract][Full Text] [Related]
47. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
[TBL] [Abstract][Full Text] [Related]
48. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
[TBL] [Abstract][Full Text] [Related]
49. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
50. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
[TBL] [Abstract][Full Text] [Related]
51. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
Tummarello D; Graziano F; Isidori P; Santo A; Cetto G; Fedeli A; Rossi G; Cellerino R
Cancer; 1996 Jun; 77(11):2251-7. PubMed ID: 8635092
[TBL] [Abstract][Full Text] [Related]
52. A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer.
Chikamori K; Kishino D; Takigawa N; Hotta K; Nogami N; Kamei H; Kuyama S; Gemba K; Takemoto M; Kanazawa S; Ueoka H; Segawa Y; Takata S; Tabata M; Kiura K; Tanimoto M;
Lung Cancer; 2009 Jul; 65(1):74-9. PubMed ID: 19056143
[TBL] [Abstract][Full Text] [Related]
53. Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
Makimoto G; Hotta K; Oze I; Ninomiya K; Nakanishi M; Hara N; Kano H; Watanabe H; Hata Y; Nishii K; Nakasuka T; Itano J; Ninomiya T; Kubo T; Ohashi K; Ichihara E; Minami D; Sato A; Tabata M; Maeda Y; Kiura K
Asia Pac J Clin Oncol; 2021 Feb; 17(1):101-108. PubMed ID: 32885583
[TBL] [Abstract][Full Text] [Related]
54. Changes in urinary excretion of endothelin-1-like immunoreactivity in patients with testicular cancer receiving high-dose cisplatin therapy.
Takeda M; Komeyama T; Tsutsui T; Mizusawa T; Go H; Hatano A; Tanikawa T
Am J Kidney Dis; 1994 Jul; 24(1):12-6. PubMed ID: 8023817
[TBL] [Abstract][Full Text] [Related]
55. Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non-small-cell lung cancer: A retrospective cohort study (HYCIS-XL).
Niggebrugge-Mentink KL; Beex-Oosterhuis MM; Ter Horst PGJ; van de Poll MEC; Dieleman HG; van Kesteren C
J Clin Pharm Ther; 2020 Oct; 45(5):1153-1158. PubMed ID: 32533904
[TBL] [Abstract][Full Text] [Related]
56. Enhancement of methotrexate nephrotoxicity after cisplatin therapy.
Goren MP; Wright RK; Horowitz ME; Meyer WH
Cancer; 1986 Dec; 58(12):2617-21. PubMed ID: 2877729
[TBL] [Abstract][Full Text] [Related]
57. Cumulative renal tubular damage associated with cisplatin nephrotoxicity.
Goren MP; Wright RK; Horowitz ME
Cancer Chemother Pharmacol; 1986; 18(1):69-73. PubMed ID: 2875808
[TBL] [Abstract][Full Text] [Related]
58. The evaluation of urinary calprotectin levels for prediction of acute cisplatin-induced nephrotoxicity.
Koçak G; Bilik G; Yeşilova A; Oyman F; Can M; Cihan Ş
Medicine (Baltimore); 2022 Jul; 101(26):e29814. PubMed ID: 35777022
[TBL] [Abstract][Full Text] [Related]
59. Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis.
Yamaguchi T; Uozu S; Isogai S; Hayashi M; Goto Y; Nakanishi T; Imaizumi K
Support Care Cancer; 2017 Apr; 25(4):1215-1220. PubMed ID: 27966021
[TBL] [Abstract][Full Text] [Related]
60. Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer.
Shord SS; Thompson DM; Krempl GA; Hanigan MH
Anticancer Drugs; 2006 Feb; 17(2):207-15. PubMed ID: 16428940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
